EA202191555A1 - Системы редактирования генов для редактирования гена трансмембранного регулятора муковисцидоза (cftr) - Google Patents
Системы редактирования генов для редактирования гена трансмембранного регулятора муковисцидоза (cftr)Info
- Publication number
- EA202191555A1 EA202191555A1 EA202191555A EA202191555A EA202191555A1 EA 202191555 A1 EA202191555 A1 EA 202191555A1 EA 202191555 A EA202191555 A EA 202191555A EA 202191555 A EA202191555 A EA 202191555A EA 202191555 A1 EA202191555 A1 EA 202191555A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- gene
- editing
- cftr
- regulator
- fluiscidosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0688—Cells from the lungs or the respiratory tract
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
В изобретении описаны высокоэффективные системы редактирования генов, содержащие нуклеазу, направляющую РНК и/или донорную матрицу, и их применение для редактирования гена трансмембранного регулятора муковисцидоза (CFTR) in vitro или in vivo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862775637P | 2018-12-05 | 2018-12-05 | |
PCT/US2019/064718 WO2020118073A1 (en) | 2018-12-05 | 2019-12-05 | Gene-editing systems for editing a cystic fibrosis transmembrane regulator (cftr) gene |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202191555A1 true EA202191555A1 (ru) | 2021-09-03 |
Family
ID=69106176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202191555A EA202191555A1 (ru) | 2018-12-05 | 2019-12-05 | Системы редактирования генов для редактирования гена трансмембранного регулятора муковисцидоза (cftr) |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210403906A1 (ru) |
EP (1) | EP3891283A1 (ru) |
AU (1) | AU2019391114A1 (ru) |
BR (1) | BR112021010753A2 (ru) |
CA (1) | CA3121781A1 (ru) |
CO (1) | CO2021007320A2 (ru) |
EA (1) | EA202191555A1 (ru) |
IL (1) | IL283631A (ru) |
JO (1) | JOP20210133A1 (ru) |
WO (1) | WO2020118073A1 (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022008557A2 (en) * | 2020-07-08 | 2022-01-13 | UCB Biopharma SRL | Modulation of cftr expression |
EP4320245A1 (en) * | 2021-04-05 | 2024-02-14 | The Board Of Regents Of The University Of Texas System | Compositions, methods and uses for treating cystic fibrosis and related disorders |
WO2022234519A1 (en) * | 2021-05-05 | 2022-11-10 | Crispr Therapeutics Ag | Compositions and methods for using sacas9 scaffold sequences |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
US20040224385A1 (en) | 2001-08-20 | 2004-11-11 | Barbas Carlos F | Zinc finger binding domains for cnn |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
AU2010327998B2 (en) | 2009-12-10 | 2015-11-12 | Iowa State University Research Foundation, Inc. | TAL effector-mediated DNA modification |
EP3556858A3 (en) * | 2014-04-09 | 2020-01-22 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating cystic fibrosis |
-
2019
- 2019-12-05 BR BR112021010753-3A patent/BR112021010753A2/pt unknown
- 2019-12-05 WO PCT/US2019/064718 patent/WO2020118073A1/en active Application Filing
- 2019-12-05 EP EP19832232.3A patent/EP3891283A1/en active Pending
- 2019-12-05 JO JOP/2021/0133A patent/JOP20210133A1/ar unknown
- 2019-12-05 AU AU2019391114A patent/AU2019391114A1/en active Pending
- 2019-12-05 CA CA3121781A patent/CA3121781A1/en active Pending
- 2019-12-05 EA EA202191555A patent/EA202191555A1/ru unknown
-
2021
- 2021-06-01 IL IL283631A patent/IL283631A/en unknown
- 2021-06-03 CO CONC2021/0007320A patent/CO2021007320A2/es unknown
- 2021-06-04 US US17/339,425 patent/US20210403906A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2019391114A1 (en) | 2021-06-24 |
EP3891283A1 (en) | 2021-10-13 |
CO2021007320A2 (es) | 2021-06-21 |
CA3121781A1 (en) | 2020-06-11 |
BR112021010753A2 (pt) | 2021-09-21 |
JOP20210133A1 (ar) | 2023-01-30 |
WO2020118073A1 (en) | 2020-06-11 |
US20210403906A1 (en) | 2021-12-30 |
IL283631A (en) | 2021-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY194032A (en) | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof | |
EA202191555A1 (ru) | Системы редактирования генов для редактирования гена трансмембранного регулятора муковисцидоза (cftr) | |
MX2020003995A (es) | Nuevas moleculas de acido nucleico artificiales. | |
IL268888A (en) | Multispecific binding proteins targeting CAIX, ANOI, mesothelin, TROP2, CEA, or CLAUDIN-18.2 | |
MX2021004214A (es) | Composiciones y metodos de inmunoterapia. | |
MX2022010611A (es) | Identificacion libre de bisulfito de modificaciones de citosina por resolucion de base. | |
EP3802828A4 (en) | RNA MODIFIED GUIDES FOR GENE EDITING | |
MX2019005076A (es) | Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2. | |
MX2019007021A (es) | Anticuerpos il-11ra. | |
MX2018010971A (es) | Compuestos y métodos para modular la tirosina cinasa de bruton. | |
EP3766228A4 (en) | VERIFICATION OF INDUSTRIAL DATA USING A SECURE DISTRIBUTED REGISTER | |
MX2021006564A (es) | Sistemas activos dinamicos acromosomicos. | |
CR20160555A (es) | Vectores de aav para la terapia génica de la retina y el snc | |
AU2015315168A8 (en) | Targeted mutagenesis in spirulina | |
CY1122644T1 (el) | Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων | |
CR20220156A (es) | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso | |
MX2021003159A (es) | Microemulsiones que contienen antioxidantes. | |
EP3547469A4 (en) | OPTICAL COMMUNICATION DEVICE AND DEVICE FOR PROVIDING SURGE LIGHT FOR OPTICAL GAINING | |
EP3864161A4 (en) | REGULATED GENE EDIT SYSTEM | |
USD729314S1 (en) | Pencil and crayon sharpener | |
SG10201806014TA (en) | Feedback canceller and hearing aid | |
EP3483658A4 (en) | IMAGE GENERATION DEVICE, READER / WRITER AND DYE CARTRIDGE | |
EP3176886A4 (en) | Optical fiber, fiber amplifier, and fiber laser | |
SG10201809621XA (en) | Plate | |
LT3236545T (lt) | Optinis modulis, lazerinio stiprintuvo sistema, būdas ir panaudojimas |